View in EDS

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Saved in:

Bibliographic Details
Title:	Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.
Authors:	Ji Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. yan.ji@novartis.com., Wang C; Novartis Pharma AG, Basel, Switzerland., Combes FP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Ho YY; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Fasching PA; University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany., Untch M; Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, Germany., Zarate JP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Crown J; St. Vincent's University Hospital, Dublin, Ireland.
Source:	Clinical pharmacokinetics [Clin Pharmacokinet] 2026 Jun 23. Date of Electronic Publication: 2026 Jun 23.
Publication Type:	Journal Article
Journal Info:	Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1179-1926
DOI:	10.1007/s40262-026-01643-3